Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG) by Schernthaner, G et al.
Schernthaner et al. Cardiovasc Diabetol  (2017) 16:137 
DOI 10.1186/s12933-017-0622-7
REVIEW
Translating recent results from the 
Cardiovascular Outcomes Trials into clinical 
practice: recommendations from the Central 
and Eastern European Diabetes Expert Group 
(CEEDEG)
Guntram Schernthaner1*, Roger Lehmann2, Martin Prázný3, Leszek Czupryniak4, Kristine Ducena5, 
Peter Fasching6, Andrej Janež7, Avraham Karasik8, Peter Kempler9, Emil Martinka10, Marina V. Shestakova11, 
Lea Smirčić Duvnjak12 and Tsvetalina Tankova13
Abstract 
Aims: These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular 
(CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD) are major 
interdependent comorbidities in patients with T2D, accounting for 50% of mortality. Following recent CV outcomes 
trial (CVOT) results, including those from EMPA-REG  OUTCOME®,  LEADER®, SUSTAIN™-6 and, most recently, the 
CANVAS study, it is essential to develop regional expert consensus recommendations to aid physicians in interpreting 
these newest data to clinical practice.
Methods: The Central and Eastern European Diabetes Expert Group (CEEDEG) followed a Delphi method to develop 
treatment algorithms to aid physicians in the clinical management of patients with T2D at high CV risk.
Results: In light of the latest CVOT results, and in particular the EMPA-REG  OUTCOME® and  LEADER® trials, the 
diagnosis, assessment, treatment choice and monitoring of patients with T2D and established CVD and/or CKD have 
been considered together with existing guidelines and presented in two reference algorithms. In addition, adherence, 
special prescribing considerations and a proposed multidisciplinary management approach have been discussed and 
are presented with the proposed algorithms.
Conclusions: The latest available high-level evidence on glucose-lowering drugs has enabled CEEDEG to develop 
practical consensus recommendations for patients with established CVD and/or CKD. These recommendations 
represent an update to international and country-level guidelines used for these patients, with the aim of providing a 
resource not only to endocrinologists, but to cardiologists, nephrologists and primary care physicians in the region.
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Background
For patients with type 2 diabetes (T2D), cardiovascular 
disease (CVD) is the single most common cause of mor-
tality [1]. The average life expectancy of a 60-year-old 
male with T2D and no history of cardiovascular (CV) 
disease (CVD) is 12 years less than his counterpart with-
out diabetes, mostly owing to a 58% increase in risk of 
CV death [2].
Historical studies investigating the potential ben-
efits of intensive glucose-lowering therapy have shown 
mixed results [3, 4], and concerns were raised that some 
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anti-diabetic agents might even be increasing CV risk in 
patients with T2D; a particular concern in light of the 
high prevalence of CV and/or renal co-morbidities in this 
patient population. Meta-analyses revealed that rosiglita-
zone was associated with a significant increase in the risk 
of myocardial infarction (MI) compared with patients 
not receiving rosiglitazone, and an increase in the risk 
of CV death that had borderline significance [5, 6]. The 
later US veterans affairs diabetes trial showed, however, 
that rosiglitazone use in older patients with T2D was 
associated with decreased risk of the primary CV com-
posite outcome and CV death, and that rosiglitazone 
use did not lead to a higher risk of MI [7]. Meta-analyses 
across study results are not designed to assess superior-
ity, are not prospective and are likely to necessitate the 
inclusion of heterogeneous study designs. To address this 
safety concern, the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) have 
therefore asked for proof of CV safety, which includes 
CV outcomes trials (CVOTs) being initiated on all new 
anti-diabetic agents to provide prospective, statistically 
powered assessments in patients with T2D in order to 
rule out excess CV risk [8–10].
CVOTs for several anti-diabetic drugs have been pub-
lished in the past few years. Although these new anti-
diabetic agents generated mostly neutral CV outcomes, 
providing welcome evidence that most of these drugs do 
not increase CV risk for patients with T2D, there were 
mixed results overall, as shown in Table 1 [4, 10].
In light of these mixed results, the swift incorporation 
of CVOT findings into international and country-level 
guidelines is therefore necessary to facilitate treatment 
decisions for improved patient outcomes. Many guide-
lines for the treatment of T2D require further updates, 
including, importantly, the Joint Position Statement 
of the European Association for the Study of Diabe-
tes (EASD)/American Diabetes Association (ADA) and 
the American College of Physicians (ACP) [11, 12]. The 
guidelines of the European Society of Cardiology (ESC) 
and the ADA, however, have recently incorporated rec-
ommendations based on the CVOT results [13, 14]. The 
Central and Eastern European Diabetes Expert Group 
(CEEDEG) was created as a responsive team of experts, 
providing regular and up-to-date clinical recommenda-
tions to be used as a companion resource for the region, 
together with the EASD/ADA position statement. By 
providing such regular follow-up publications, it is 
anticipated that important data on safety and both posi-
tive and negative outcomes can be rapidly disseminated. 
CEEDEG is composed of 14 members, six of whom have 
been involved in the generation of their national clinical 
guidelines, including the Swiss Society of Endocrinology 
and Diabetes (SSED/SGED) [15], the Hungarian Diabe-
tology Society [16], the Slovak Diabetes Association [17], 
the Russian Association of Endocrinologists [18], and the 
Austrian Society for Diabetes (ÖDG) [15, 19]. All mem-
bers hold senior positions in medical schools in their 
respective countries and belong to, or serve on, a variety 
of professional bodies throughout Central and Eastern 
Europe. The recommendations herein have been derived 
via a Delphi process, which is a structured tool to achieve 
unbiased consensus [20].
Methods
CEEDEG was formed to provide a panel of experts in 
Central and Eastern Europe who could regularly review, 
interpret and translate new data from clinical studies into 
clinical recommendations for everyday practice.
The process was structured to generate expert clinical rec-
ommendations to complement the current EASD/ADA 
Table 1 Key cardiovascular and renal outcomes for CVOTs of glucose-lowering agents
This is not a head-to-head comparison
SUSTAIN-6™ was a non-inferiority study, and testing for superiority was not a pre-specified endpoint [22, 23, 25, 28, 29, 33]
CVOT cardiovascular outcomes trial, MACE major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke), RRR relative 
risk reduction
Reduction in  
3-point MACE
Reduction in 
CV death
Reduction in  
all-cause mortality
Reduction in 
hospitalisation for HF
Reduction in doubling 
of serum creatinine
EMPA-REG  OUTCOME®
 RRR (%) 14 38 32 35 44
 p value 0.04 < 0.001 < 0.001 0.002 < 0.001
LEADER®
 RRR (%) 13 22 15 13 12
 p value 0.01 0.007 0.02 NS NS
SUSTAIN™-6
 RRR (%) 26 2 + 5 + 11 + 28
 p value 0.02 NS NS NS NS
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guidelines in light of the data from EMPA-REG  OUTCOME®, 
 LEADER®, SUSTAIN™-6 and the other CVOTs that had been 
published at the time of the Delphi process [21–25]. Agreeing 
on the necessity of producing such recommendations was an 
inclusive initial part of the proceedings.
A semi-structured questionnaire with multi-factor 
open questions was circulated (Additional file  1). The 
questionnaire related to patients with T2D and estab-
lished cardiac and/or renal disease, as these are the 
patient populations who would most benefit from recom-
mendations based on CVOT data. The recommendations 
generated were sorted, de-duplicated and used to cre-
ate a second questionnaire (Additional file  2), in which 
respondents scored each proposed recommendation on a 
Likert-like scale (1-totally disagree; 2-disagree; 3-unsure; 
4-agree; 5-totally agree). Only those recommendations 
for which at least 80% of respondents awarded a score 
of 4 or 5 were considered to have reached consensus. 
Respondents were encouraged to add additional com-
ments, suggestions or refinements to the proposed state-
ments. Additional suggestions and refinements were 
included in a third-round questionnaire, which was 
scored in the same way as the second (Additional file 3).
Following the Delphi process, a face-to-face meeting 
of CEEDEG was convened with the aim of reaching final 
consensus and addressing any outstanding issues from 
the process. In-depth discussions were held and grouped 
according to clinical expertise to refine and clarify points 
of particular complexity, then all members met to verify 
or reject statements together, thereby achieving a full and 
final consensus.
Recommendations of CEEDEG
CEEDEG noted that for those patients who have T2D 
but do not have established CVD or chronic kidney 
disease (CKD), the current EASD/ADA guidelines 
[11] should be followed as no further data on thera-
pies for these patients have been published. However, 
for patients with either or both of these comorbidi-
ties, two algorithms were developed: one for patients 
with T2D and established CVD (Fig. 1), and the other 
for patients with T2D and established CKD with or 
without established CVD (Fig.  2). It is hoped that 
these additional tools will be used alongside the Euro-
pean guidelines as an aid to decision-making when 
prescribing glucose-lowering therapies. It should be 
Fig. 1 Treatment algorithm for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD): initial considerations for therapy 
and therapy choice flow diagram. Items in green signify the items of specific focus in these recommendations. Dashed lines indicate injectable 
therapies. ACR albumin:creatinine ratio, BMI body mass index, BP blood pressure, CKD chronic kidney disease, CVD cardiovascular disease, DPP-
4i dipeptidyl peptidase 4 inhibitor, ECG electrocardiogram, GFR glomerular filtration rate, eGFR estimated GFR, DPP-4-i DPP-4 inhibitor, GLP-1 RA 
glucagon-like peptide 1 receptor agonist, HF heart failure, hypo hypoglycaemia, int/CI intolerance or contraindication, MET metformin, NYHA New 
York Heart Association, SGLT2i sodium–glucose co-transporter 2 inhibitor, SU sulfonylurea, T2D type 2 diabetes, TZD thiazolidinedione
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emphasised that all agents referred to within these rec-
ommendations should be used in accordance with the 
relevant summary of product characteristics or pre-
scribing information for the country in which they are 
being prescribed.
Diagnosis/assessment
The evaluation of all patients should include the follow-
ing parameters: age, sex, height, weight and body mass 
index (BMI). The medical history should document the 
time since diagnosis of T2D, any episodes of prior severe 
hypoglycaemia and the presence of, or history of, concur-
rent pancreatitis or genital infection.
For patients with established CKD, any retinopathy, 
autonomic neuropathy [26], haematological disorders or 
renal infections should also be ascertained. Patients with 
established CKD, and at high risk of CV events but with 
as yet undiagnosed CVD, should be actively screened for 
the presence of CV risk factors.
The presence of any other comorbidities and current 
pharmacological therapies should be determined and 
taken into consideration when making treatment deci-
sions, to ensure that the patient receives optimally indi-
vidualised care to achieve the best possible outcome.
A comprehensive investigative work-up is needed to 
make best-practice treatment decisions. Clinical, labora-
tory, and, for certain patients, other physiological evalua-
tions should be performed:
  • Clinical: blood pressure sitting and standing, and 
classification of heart failure (HF) according to New 
York Heart Association functional criteria [27].
  • Laboratory: 
• HbA1c levels; lipid profile; glomerular filtration rate 
(GFR)/estimated GFR (eGFR), urinary albumin/
creatinine ratio (UACR) and proteinuria.
•  For patients with CKD, urinalysis.
Fig. 2 Treatment algorithm for patients with type 2 diabetes (T2D) and established chronic kidney disease (CKD), with or without cardiovascular 
disease (CVD): initial considerations for therapy and therapy choice flow diagram. Items in green signify the items of specific focus in these recom-
mendations. Dashed lines indicate injectable therapies. ACR albumin:creatinine ratio, BMI body mass index, BP blood pressure, CKD chronic kidney 
disease, CVD cardiovascular disease, DPP-4i dipeptidyl peptidase 4 inhibitor, ECG electrocardiogram, GFR glomerular filtration rate, eGFR estimated 
GFR, DPP-4-i DPP-4 inhibitor, GLP-1 RA glucagon-like peptide 1 receptor agonist, HF heart failure, hypo hypoglycaemia, int/CI intolerance or contrain-
dication, MET metformin, NYHA New York Heart Association, SGLT2i sodium–glucose co-transporter 2 inhibitor, SU sulfonylurea, T2D type 2 diabetes, 
TZD thiazolidinedione
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•  Brain natriuretic peptide (BNP)/N-terminal pro-
hormone of BNP (NT-proBNP) should be consid-
ered in patients having symptoms or signs of HF.
•  Other causes/kidney diseases associated with mac-
roalbuminuria, including the detection of nondia-
betic nephropathy, should be ruled out.
•  Physiological measurements: 
•  For patients who are at particular risk of MI, 
electrocardiogram (ECG) should be performed.
•  For patients with CKD, kidney/cardiac ultra-
sound should be considered depending on clini-
cal need.
Clinical management
CEEDEG, in common with the EASD/ADA guidelines, 
recommended a patient-centric approach to treatment 
to enable the optimal combination of ideal therapy and 
patient compliance.
Adherence rates and patient education
Several factors need to be taken into consideration to 
build on long-term adherence rates and good self-man-
agement by patients:
  • Therapeutic choices should be explored with the 
patient, making use of decision aids where rel-
evant, and should take place within the context of 
the patient’s priorities, goals and preferred level of 
involvement.
  • Treatment strategies should be kept as simple as pos-
sible to reduce the apparent treatment burden, e.g. 
the use of dual-agent therapies.
  • Treatments should be carefully and thoroughly 
explained to patients on multiple occasions, and reit-
erated by all practitioners involved in the patient’s 
care.
  • The patient’s age should also be considered when 
selecting treatment, taking into account age-related 
comorbidities and the special repercussions of pos-
sible adverse events, such as falls in elderly or frail 
patients.
  • Full dietary evaluation (rather than simple caloric 
intake) should be performed for all patients.
  • The agreed management program should then be 
implemented and run by clinical specialists and pri-
mary care physicians, ideally involving a dietitian 
and, if needed, a psychologist (Table 2).
Glycaemic control
CEEDEG recommended a treat-to-target approach based 
on reducing HbA1c levels to below 7.0% (53  mmol/mol); 
however, individualisation is key [28]. For elderly and frail 
patients with significant CVD or CKD co-morbidities, or 
who are prone to hypoglycaemia, more relaxed targets 
Table 2 Specialities for inter-professional, multidisciplinary team-based type 2 diabetes care for a comprehensive multi-
factorial risk-reduction strategy in the context of cardiovascular comorbidity
ACR albumin:creatinine ratio, BMI body mass index, BP blood pressure, CV cardiovascular, CVD CV disease, ECG electrocardiogram, ECHO echocardiogram
Speciality Key functions and areas of responsibility
Diabetologist/endocrinologist Therapy induction including patient education: explanation of therapy choice, side-effects, complications, acute 
emergencies
Sets BP, lipid, HbA1c targets
Trained in cardiology/nephrology/internal medicine
Internist Follow-up care, including monitoring of BP, lipid targets and controls, ECG, echocardiagram imaging
Trained in diabetology (patients with diabetes who are complicated to treat should always be referred to diabe-
tologists/endocrinologists)
Nephrologist Renal function, ACR, BP control
Lipid targets
Cardiologist Essential for CVD and CV risk management
Trained in diabetology
Nutritionist/dietician Dietary counselling at therapy induction
A key figure in patient education together with diabetologist/endocrinologist
Monitoring of glucose control and intake, and body weight
Individual diet plans for weight reduction if needed, and/or long-term weight maintenance
Nurses Education programmes
Individual support
BMI monitoring
Certified diabetes educator Smoking cessation
Diabetes education at treatment induction and for re-enforcement
Education programmes, team work
Consistent and structured education that is crucial for adherence, motivation and minimising barriers to treatment
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in the range of 7.5 − 8.0 + % (58.5–63.9 mmol/mol) may 
be applied. This can be tightened to 6.0–6.5% (42.1–
47.5  mmol/mol) in younger, healthier patients or those 
without significant CVD. Overall, it is important to set the 
target HbA1c level appropriately for each individual to avoid 
hypoglycaemia and any other drug-related adverse effects.
Cardiovascular protection
As discussed in the introduction, CV mortality remains 
the main cause of death in this patient group despite recent 
advances in therapies for T2D. Intensive glycaemic control 
does not always lead to better CV outcomes [29]; there-
fore, focusing solely on glucose lowering may not help to 
address macrovascular complications in T2D. Although 
the target of modern diabetes therapies in the recent past 
has been a safe and effective blood glucose reduction [11], 
recent results of trials dedicated to CV outcomes clearly 
demonstrate that innovative diabetic drugs such as empa-
gliflozin and liraglutide can add significant benefit to out-
comes for patients with T2D in terms of a reduction in CV 
death [23, 30–32]. These important clinical results have 
led to a new duality paradigm for T2D treatment, whereby 
both the improvement of glycaemic control and the reduc-
tion of CV morbidity and mortality become an integral 
part of the treatment of T2D. Therefore, CV risk and pro-
tection should always be considered when determining 
therapeutic regimens for patients with T2D.
Type 2 diabetes therapeutic regimens
Monotherapy
Although monotherapy with metformin is commonly 
used in patients with no CV comorbidities, the early 
combining of metformin therapy together with agents 
that reduce CV risk should be preferred in patients with 
T2D and established CVD.
Progressing patients from mono- to combination 
therapy should be considered on an individual basis, 
depending on the patient’s investigation data, and is rec-
ommended to achieve good glycaemic control and better 
CV and renoprotective outcomes.
Combination therapy
Current glucose-lowering therapies comprise six classes, 
each with differing combinations of attributes over and 
above decreasing HbA1c, such as effects on CV risk, renal 
outcomes, blood pressure and weight. Suitability for use in 
the presence of nephropathy should be considered when 
choosing agents for multiple combinations (Table 3).
Dual therapy
The choice of agent for initial combination with met-
formin can be streamlined on the basis of patient comor-
bidities and characteristics.
SGLT2 inhibitors
For patients with T2D and CVD, sodium–glucose co-
transporter 2 (SGLT2) inhibitors should be considered 
for use after metformin monotherapy in those with a 
GFR > 60 ml/min (or > 45 ml/min or above in countries 
where this is the indicated threshold for empagliflozin/
canagliflozin prescribing).
Current evidence from the EMPA-REG  OUTCOME® 
trial showed that empagliflozin significantly reduced 
the time to the first occurrence of the primary com-
posite endpoint of 3-point major adverse cardiovas-
cular events (3-P MACE): CV death, non-fatal MI 
or non-fatal stroke (HR: 0.86; 95% CI 0.74–0.99) [21, 
30, 33, 34]. The primary endpoint improvement was 
mostly driven by a 38% relative risk reduction (RRR) 
in the key outcome of CV mortality (HR 0.62; 95% CI 
0.49–0.77). Hospitalisation for HF, a defined secondary 
outcome, was also significantly lower in the empagli-
flozin group compared with placebo (HR 0.65; 95% CI 
0.50–0.85; p  <  0.002), likewise, there was a significant 
lowering of all-cause mortality with the addition of 
empagliflozin to standard of care (HR 0.68, 95% CI 0.57–
0.82; p  <  0.001). This SGLT2 inhibitor should therefore 
be preferentially chosen for patients at high risk of CV 
events [33].
For patients with T2D and CKD, empagliflozin was 
recommended in early combination with metformin 
and renin–angiotensin system (RAS) blockade, as it can 
reduce the rate of renal decline. Incidence of or worsen-
ing nephropathy occurred in fewer patients in the empa-
gliflozin group than in the placebo group (HR 0.61; 95% 
CI 0.53–0.70). In patients treated with empagliflozin 
compared with placebo there was a RRR of the doubling 
of serum creatinine levels of 44%, and a 55% RRR of 
renal-replacement therapy being initiated [30].
Owing to the documented CV benefits mentioned 
above, empagliflozin should be considered as the drug of 
preference for patients with T2D and CKD who also have 
established CVD.
Empagliflozin may also be used as a monotherapy if 
the patient is intolerant to metformin or if metformin is 
contraindicated.
GLP-1 receptor agonists
Glucagon-like peptide 1 (GLP-1) receptor agonists (pref-
erentially liraglutide) should be considered in patients 
with a GFR below 60  ml/min but greater than 30  ml/
min. The results of the  LEADER® CVOT of liraglutide in 
patients with T2D and at high risk of CV events showed 
lower CV-related and all-cause mortalities in patients 
treated with liraglutide compared with placebo (HR 
0.78; 95% CI 0.66–0.93 and HR 0.85; 95% CI 0.74–0.97, 
respectively) [23]. These agents are also recommended 
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for patients with a BMI > 30, owing to their documented 
benefits in weight reduction. GLP-1 receptor agonists 
may also be used as a single agent in patients intolerant 
to metformin.
DPP-4 inhibitors
CVOTs of the dipeptidyl peptidase 4 (DPP-4) inhibitors 
saxagliptin, alogliptin and sitagliptin have shown neutral 
results in which neither an increase nor a decrease was 
seen in the rate of ischaemic events in patients treated 
with these agents when compared with placebo, although 
the rate of hospitalisation for HF was increased for sax-
agliptin [35–37]. For patients who are unsuitable for 
either an SGLT2 inhibitor or a GLP-1 receptor agonist, 
such as those with an eGFR below 60 ml/min (30 ml/min 
for patients with CKD), DPP-4 inhibitors (oral) may be 
considered.
Insulin
Basal insulin injections are an option for all patients 
However, it is recommended that their early use is 
restricted to those patients with a GFR below 60 ml/min 
(15 ml/min for patients with CKD) and who cannot be 
prescribed any of the aforementioned agents. Other-
wise, this treatment option should be reserved for later 
use.
Table 3 Current glucose-lowering therapies and their key attributes. Adapted from the SGED/SSED guidelines [13, 15], 
except where indicated
Agents in italics have a higher level of evidence for reduction of micro- and macrovascular complications and mortality or fewer side-effects
CV cardiovascular, DPP-4 dipeptidyl peptidase 4, GLP-1 glucagon-like peptide 1, LAR long-acting release, SGLT2 sodium–glucose co-transporter 2, SU sulfonylurea, TZD 
thiazolidinedione
a A meta-analysis of the CV safety of dulaglutide in patients with T2D [52]
b Astudy that predates the CVOT mandate demonstrated significant reduction in a CV composite outcome. The study was a post hoc analysis of a prospective clinical 
trial [41, 53]
c A double-blind, randomised trial that compared pioglitazone with metformin as monotherapies found that the HbA1c reduction was similar between the two drugs 
[42, 54]
d An observational prescription-event monitoring study that showed treatment with pioglitazone was associated with a low incidence of hypoglycaemia [43, 55]
e Also available in combination with metformin
Class Beneficial effect on CV outcomes Beneficial effect on HbA1c levels Effect on weight Hypoglycaemic risk
Metformin (oral) Moderate (long-term) Moderate Moderate decrease Neutral
SGLT2 inhibitors (oral)
 Empagliflozine High (empagliflozin and canagliflozin) Moderate to high High decrease Neutral
 Canagliflozin
 Dapagliflozin
GLP-1 receptor agonists (injection)
 Liraglutide High (liraglutide and semaglutide) High Very high decrease Neutral
 Semaglutide
 Exenatide
 Exenatide LAR
 Dulaglutidea
DPP-4 inhibitors (oral)
 Sitagliptine Neutral Moderate Neutral Neutral
 Alogliptine
 Linagliptine
 Saxagliptin
 Vildagliptine
Insulins (injection)
 Insulin degludec Neutral High Neutral High
 Insulin glargine
TZDs (oral)
 Pioglitazone High?b Moderate?c Increased
SUs (oral)
 Gliclazide Neutral Moderate Neutral Moderate
 Glimepiride
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Other type 2 diabetes treatment agents
Pioglitazone and sulfonylureas (SUs) should be used 
with caution in all patients, owing to the high risk of 
congestive HF in the former and hypoglycaemia in the 
latter of these agents. Where prescribing these classes 
is necessary, e.g. for financial/reimbursement reasons, 
compounds with a short duration of action (no active 
metabolites), such as gliclazide, are preferred, owing to 
the evidence of relative safety compared with other class 
members.
Triple therapy
If, after 3  months of dual combination therapy, the 
HbA1c target is not achieved, the addition of a third 
therapeutic agent should be considered as second-line 
combination therapy. Here, the choice of additional agent 
should largely depend on responses to the existing com-
bination, as well as on the patient’s co-morbidities.
For all patients who are already taking metformin plus 
an SGLT2 inhibitor for its CV risk-reduction benefits, the 
recommended third agents are, in order of preference, a 
GLP-1 receptor agonist, a DPP-4 inhibitor or basal insu-
lin. CEEDEG recommended that patients who do not 
show a decrease in HbA1c level from treatment with 
empagliflozin should not be simply switched to a GLP-1 
receptor agonist, owing to the documented important 
cardio- and renoprotective effects of empagliflozin.
The agents that are of most benefit to patients with 
T2D and CVD who are already being treated with met-
formin and a GLP-1 receptor agonist are either an SGLT2 
inhibitor or basal insulin.
For those patients who received a DPP-4 inhibitor with 
metformin in the first instance, then either the DPP-4 
inhibitor should be replaced by a long-acting GLP-1 
receptor agonist, or a basal insulin or gliclazide should be 
prescribed. For patients who received basal insulin with 
metformin, add an SGLT2 inhibitor, a GLP-1 receptor 
agonist or a DPP-4 inhibitor, depending on the GFR.
A quadruple combination should be initiated if, after 
a further 3  months of triple combination therapy, the 
patient has still not achieved their individual target 
HbA1c level. For those patients who are taking oral ther-
apies, an injectable therapy should be added: a GLP-1 
receptor agonist, basal insulin or mealtime insulin. If the 
patient is receiving a GLP-1 receptor agonist, then basal 
insulin should be the next agent. If the patient is already 
on optimally treated basal insulin, then either a GLP-1 
receptor agonist or mealtime insulin should be added, 
depending on whether they are already taking a GLP-1 
receptor agonist. If patients remain refractory to treat-
ment, then consider adding a thiazolidinedione (TZD) or 
an SGLT2 inhibitor, also depending on the existing thera-
peutic agents that the patient is receiving.
Monitoring/evaluation of response to treatment
As suggested above, to determine the efficacy of glucose-
lowering treatments, and to monitor changes in CV 
risk factors, regular monitoring of the patient should be 
conducted at 3-monthly intervals. The parameters that 
should be evaluated are similar to those for initial assess-
ment, and should remain comprehensive to manage both 
glucose levels and CV risk.
Clinical examination should include blood pressure 
and BMI. The laboratory tests should ascertain glucose 
levels to allow for correction of insulin/anti-hypertensive 
drugs if the patient has been experiencing hypoglycae-
mia. Laboratory tests should also measure HbA1c level, 
lipid profile, and proteinuria, GFR/eGFR and UACR.
The SGLT2 inhibitor empagliflozin should be with-
drawn if the eGFR has reduced to below 45  ml/min as 
indicated; however, data from clinical studies show that 
benefits may still be seen in patients down to an eGFR of 
30 ml/min [30, 33]. The GLP-1 receptor agonist liraglu-
tide should also be withdrawn when a minimum eGFR of 
30 ml/min is reached.
A repeat ECG should be performed as part of the fol-
low-up to monitor any changes in CV status.
Cardiac/lipid control
In addition to glucose-lowering agents, patients should 
also receive an anti-platelet aggregation agent, beta-
blocker, angiotensin-converting enzyme (ACE) inhibitor, 
angiotensin receptor blocker (ARB) and statin therapies 
if indicated.
Special prescribing considerations
Although basal and other insulins have been somewhat 
superseded by the new generation of anti-hyperglycae-
mic drugs, they should not be excluded where needed. 
When prescribing insulins, however, the latest evidence 
should be considered, which suggests that insulin is best 
used alongside more modern drugs. Insulin has good 
glucose-lowering effects, but can lead to hypoglycaemia 
if not carefully prescribed according to the patient’s life-
style; therefore, its therapeutic effect should be carefully 
evaluated. For patients who are receiving other glucose-
lowering agents that may offer other benefits, such as 
CV and renal protection, but who are not achieving their 
target HbA1c levels, insulin in combination with more 
modern drugs may enable them to control both aspects 
of their condition. CEEDEG felt that the evidence for the 
use of insulin as a monotherapy does not warrant its use 
in this way, especially for the older, short-acting forms.
Elderly patients
Patients in the upper age ranges (75 years and older) are 
highly variable in terms of individual fitness and general 
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lifestyles. Although care should be taken to avoid hypo-
glycaemia and its associated increased risk of falls when 
treating frail elderly patients with T2D and CVD, it 
should be taken into account that the maximum CV ben-
efits derived from the SGLT2 inhibitor empagliflozin in 
the EMPA-REG  OUTCOME® study were seen among 
the older participants, and this population is also more 
likely to suffer from CV and renal comorbidities. Preven-
tative measures should therefore be taken to avoid hypo-
volaemia when prescribing empagliflozin in this patient 
group. In the  LEADER® study of liraglutide, however, 
patients aged over 60 years experienced fewer CV events 
in the placebo arm than in the treatment arm [22, 23].
As with all other therapies, therefore, patient prefer-
ence should be taken together with the medical history 
when choosing an appropriate agent or agents.
Class effect
No strong evidence has yet been found for a class effect 
regarding positive CV outcomes of anti-diabetic agents 
(Table 4 and Additional file 4: Table S1), although over-
all, no increased CV risk has been observed [10]. For 
example, CVOTs for GLP-1 receptor agonists and DPP-4 
inhibitors have shown mixed results depending on the 
individual drug [23, 25, 35–38]. In the SGLT2 inhibitor 
class, although the EMPA–REG  OUTCOME® study and 
CANVAS program differ (for example by study design 
and the pharmacological characteristics of the drugs), 
the results of both trials showed a significant reduc-
tion on the composite endpoint (3P-MACE); however, 
individual components of 3P-MACE and key secondary 
outcomes differed greatly [33, 39]. In the EMPA-REG 
 OUTCOME® study, CV death had a relative risk reduc-
tion of 38% (95% CI 0.49–0.77), whereas in the CANVAS 
Program CV death was not significantly reduced (13% 
RRR, 95% CI 0.72–1.06). Additionally, in the EMPA-REG 
 OUTCOME® study the key secondary outcomes of all-
cause mortality (RRR 32%, 95% CI 0.57–0.82, p < 0.001), 
HHF (RRR 35%, 95% CI 0.50–0.85, p  <  0.001) and the 
composite renal outcome (RRR 46%, 95% CI 0.31–0.85, 
p  <  0.001) all showed a statistically significant benefit 
when adding empagliflozin versus placebo to standard of 
care [33]. By contrast, in the CANVAS Program none of 
the secondary outcomes showed a statistical benefit [39]. 
This is in part owing to all-cause mortality not being sig-
nificantly reduced in the CANVAS Program (13% RRR, 
95% CI 0.74–1.01) after which all other secondary out-
comes analysed in the sequential hypothesis testing plan 
can only be interpreted as exploratory, such as HHF (33% 
RRR, 95% CI 0.52–0.87) and the composite renal out-
come (RRR 40%, 95%CI 0.47–0.77). In contrast, EMPA-
REG  OUTCOME® was powered sufficiently to achieve 
significance in both HHF (RRR 35%, 95% CI 0.5–0.85, 
p < 0.001) and the composite renal outcome (RRR 46%, 
5% CI 0.31–0.85, p  <  0.001) [30, 33, 39]. An additional 
difference between SGLT2 inhibitors is the observation 
that there was an increased signal for lower limb amputa-
tions related to canagliflozin use in the CANVAS studies, 
an outcome that, although observed at a higher rate in 
patients with diabetes than in the general population, has 
not been observed in any of the empagliflozin or dapagli-
flozin studies to date [39–44].
Real world evidence studies
Currently, some agents such as exenatide and dapagliflo-
zin only have CV data from meta-analyses or observa-
tional studies [45, 46]. Recently published results from the 
real-world evidence observational study CVD-REAL, in 
which the risk of HHF in individuals with T2D who had 
been newly initiated on SGLT2 inhibitors (canagliflozin, 
dapagliflozin or empagliflozin) was compared to other 
glucose-lowering drugs (oGLD), have shown similar 
trends for risk reductions in HF and all-cause mortality 
associated with SGLT2 inhibitor use [47].This held true 
for all six countries involved in the study, despite differ-
ences in the background treatment and the use of differ-
ent SGLT2 inhibitors in the US and Europe. Furthermore, 
Table 4 Table of  3-point MACE for  CVOT studies to  date. 
Adapted from [39, 50, 51]
This is not a head-to-head comparison
CVOT cardiovascular outcomes trial, MACE major adverse cardiovascular events 
(cardiovascular death, non-fatal myocardial infarction or non-fatal stroke), NS 
not significant
a SUSTAIN™-6 was a non-inferiority study, and testing for superiority was not a 
pre-specified endpoint
Antidiabetic drug 3P-MACE hazard 
ratio (HR)
p value
PROactive Pioglitazone 0.84 (95% CI 
0.72–0.98)
0.02
ORIGIN Insulin glargine 1.02 (95% CI 
0.94–1.11)
NS
SAVOR Saxagliptin 1.00 (95% CI 
0.89–1.12)
NS
EXAMINE Alogliptin 0.96 (95% CI 
0.80–1.15)
NS
ELIXA Lixisenatide 1.02 (95% CI 
0.89–1.17)
NS
TECOS Sitagliptin 0.98 (95% CI 
0.89–1.08)
NS
EMPA-REG 
 OUTCOME®
Empagliflozin 0.86 (95% CI 
0.74–0.99)
0.038
LEADER® Liraglutide 0.87 (95% CI 
0.78–0.97)
0.01
SUSTAIN™-6 Semaglutide 0.74 (95% CI 
0.58–0.95)
< 0.001a
CANVAS-program Canagliflozin 0.86 (95% CI 
0.75–0.97)
0.02
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as both HF and the subclinical forms of HF are amongst 
the earliest vascular complications seen when following 
up diabetic patients who do not have CVD at baseline 
[48], it may be suggested that these patients in CVD-
REAL benefited from the early use of SGLT2 inhibitors. 
Of note, there were clear differences between the out-
comes in the propensity-matched CVD-REAL and the 
double-blind, randomised, placebo-controlled, CANVAS 
Program cohorts, despite canagliflozin comprising the 
largest overall component of the SGLT2 inhibitors in the 
CVD-REAL study [39, 47]. For example, in the CANVAS 
Program, although the combined primary endpoint of 
3P-MACE was reduced by 14%, there was no significant 
reduction in all-cause mortality, yet in the CVD-REAL 
US cohort, where 75% of patients were receiving cana-
gliflozin, mortality was reduced in the SGLT2 inhibitor 
group by 62% (HR 0.38, 95% CI 0.29–0.50) [39, 47, 49]. 
This is most likely to be as a result of the differing meth-
odologies of the two studies and known limitations of 
using retrospective data. We therefore feel that although 
well-performed observational studies showing the same 
trend can lend support to results that have been obtained 
from RCTs, only prospective well-performed CVOTs, 
in which strict study criteria, equalisation of baseline 
characteristics, and elimination of observer bias, can 
offer robust evidence of CV benefit. Until the results of 
the dapagliflozin DECLARE CVOT study become avail-
able in 2018, we cannot be confident in a class effect 
for the SGLT2 inhibitor class. We currently advise that 
when using the treatment algorithms physicians should 
continue to evaluate each of the members of any of the 
classes on the basis of their individual efficacy and safety 
data [23, 33, 35–38].
Multidisciplinary management
A key aspect of therapy for patients with T2D and 
comorbidities is the provision of a multidisciplinary 
team, the members of which contribute in complemen-
tary ways to improving patient outcomes. CEEDEG rec-
ommended the specialities that should be included in the 
multidisciplinary team and suggested their key functions 
and responsibilities within the team (Table 3).
Discussion
Patient outcomes are best served by the rapid implemen-
tation of emerging superior therapies, putting pressure 
on clinical guideline groups to continuously update their 
outputs. The addition of interim recommendation pub-
lications to be used in tandem with existing guidelines 
will enable a swifter response to a continuously changing 
therapeutic landscape. Recent data from CVOT studies 
of anti-diabetes drugs, and the anticipation of a stream of 
further CVOT results becoming available in the future, 
mean that the CEEDEG objective of providing regular 
companion recommendations is a welcome initiative.
By following a structured process, unbiased consensus 
treatment algorithms were derived that take into consid-
eration data from CVOTs on the CV and renoprotective 
aspects of newer anti-diabetic agents and establish their 
place in the therapeutic landscape. This initiative inter-
prets the data in such a way as to enable prescribing phy-
sicians to more easily determine the optimum treatment 
regimen for both the medical and lifestyle needs of their 
patients with T2D and CVD, or with T2D and CKD with 
or without CVD.
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